AzTrials
AzTrials

StrokeiTMSNCT06153017

iTMS - Implementing Transcranial Magnetic Stimulation (TMS) to Assess Cortico-spinal Tract Integrity

An observational study of Stroke, run by University of Aarhus at 1 site in Denmark.

Active, not recruiting

Under way, not looking for participants. Everyone needed has enrolled. The study is still running.

Official record
Search all trials

Trial summary

Reliable prediction of upper limb (UL) function can guide clinicians in choosing relevant treatment, helps to set realistic goals for rehabilitation and will contribute to personalized and effective rehabilitation. TMS has been identified as a strong predictor of future UL function after stroke. Read more about this study

Who is it for?
Ages 18 years and older
Conditions the study is for
Stroke
How many people
100 participants
Where
1 siteDenmark
Study dates
1 May 2023to 31 Dec 2025
Phase
Observational
Are there results?
Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Study population: We include patients with stroke and severe paresis or paralysis of an upper limb after stroke.

Who may be able to join

  • admitted to rehabilitation within 21 days after stroke
  • severe UL impairment, either paralysis (no active movement), or severe paresis, defined as Fugl-Meyer Assessment <17 or Shoulder Abduction Finger Extension (SAFE) score < 5
  • At least 18 years old
  • able to provide informed consent and comply with examination procedures

Who cannot join

  • Epilepsy
  • Metal implants in the head
  • Other implanted electronics (cardiac pacemaker, defibrillator, cochlear implant, medication pump)
  • Skull fracture or serious head injury
  • Pregnancy

Trial locations and contacts

1 site in 1 country.

Denmark1 site
  • Hammel Neurorehabilitation Centre and University Research Clinic

    Hammel, Aarhus, 8450

Other trials in Denmark

About this study

Reliable prediction of upper limb (UL) function can guide clinicians in choosing relevant treatment, helps to set realistic goals for rehabilitation and will contribute to personalized and effective rehabilitation. TMS has been identified as a strong predictor of future UL function after stroke. With this project, the investigators want to implement the standard use of TMS examination for a defined patient group in the clinical setting and systematically evaluate the implementation process. The impact and perceived value of TMS in the clinical setting will be evaluated and the predictive value of TMS for the specific patient population will be assessed.

Read the detailed description

Design Design: A prospective longitudinal implementation study. Setting and population: The implementation will take place at Hammel Neurorehabilitation Centre and University Research Clinic. The target population are patients with stroke.

Management The study will be organized by the Research Unit at Hammel Neurocenter, Iris Brunner, associate professor, PhD, in collaboration with the Center Management represented by head physician Kåre Eg Severinsen, MD, PhD and the unit for professional development, represented by Camilla Biering Lundquist PhD.

Evaluation of the implementation The RE-AIM framework, and its extension, the Practical Implementation Sustainability Model (PRISM) framework will be applied to guide and evaluate the implementation process. The RE-AIM framework has been used in numerous studies and hosts a homepage with comprehensive online resources for planning, evaluating and reporting implementation studies.

Briefly, it consists of the following components to evaluate the success of an implementation:

Reach. Refers to percent of individuals who are reached by the intervention. In the context of the present study, Reach would describe the number of patients for whom the TMS examination would be relevant, and the percentage of patients who received TMS, and reasons for not being examined.

  • Evaluation of Reach through monitoring of 4 selected wards with the help of the Business Intelligence (BI) portal.

Effectiveness: Entails the measurement of primary and broader outcomes. In this study, Effectiveness would assess the prediction accuracy for the specific population at the hospital.

  • Evaluation of Effectiveness. Fifty patients will be recruited consecutively from all wards at Hammel Neurorehabilitation Center's sites Hammel and Skive. Follow-up assessments of UL function will be conducted at 3 months post-stroke with the tests of UL function described in 3d. It will be assessed if individual predictions based on TMS and clinical tests will reach a specificity of 80% or more. In addition, sensitivity, PPV, NPV and overall accuracy/ CCP including 95% CI will be calculated.

Adoption. The level of actual uptake of the new intervention. Specifically in this study the number of referrals of relevant patients from different wards. Moreover, the number of involved staff (therapists, MDs) with a positive attitude to the TMS examination.

  • Evaluation of adoption will based on quantitative data from monitoring, questionnaires, and interviews.

Implementation. Description of the actual resources and cost allocated, intervention fidelity, and acceptance.

  • Implementation is evaluated with regard to intervention fidelity. In this case, can patients be examined with TMS within the planned time after stroke and is the workload for trained examiners distributed as agreed on.

Maintenance. Measures the long-term attrition to an intervention on an individual and a setting level.

  • Among others, the following questions will be addressed: Are the potential obstacles identified in previous components of reach addressed? Is the rate of patients referred to TMS stable over time? Can examination skills be maintained or is there need for a boost? Has new staff been introduced to perform the TMS procedure? Based on these questions and the feedback from questionnaires and interviews the investigators will continuously respond to threats to maintenance and adapt maintenance strategies accordingly.
Conditions
Stroke
Keywords
Transcranial Magnetic Stimulation, Upper limb function, Stroke, Neurorehabilitation, Implementation, Biomarker
Medical subject headings
Stroke

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Action Research Arm Test

    Assesses arm motor function, range 0-57 (best)

    Measured: 3 months after stroke

Secondary outcomes (2)
  1. Shoulder Abduction Finger Extension Test

    Assesses impairment for shoulder abduction and finger extension (0-10 best)

    Measured: 3 months after stroke

  2. Fugl-Meyer Motor Assessment Upper Limb (0-66 best)

    Assesses upper limb motor impairment

    Measured: 3 months after stroke

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted1 Dec 2023
  2. Study start1 May 2023
  3. Primary completion31 Dec 2025 (estimated)
  4. Study completion31 Dec 2025 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Cohort
Time perspective
Prospective
Enrolment
100 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT06153017
Sponsor's protocol ID
iTMS786101
Acronym
iTMS
Status last verified
May 2025
First submitted
14 Jun 2023
Last updated
21 May 2025
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No

Publications

  • Feldbaek RM, Brunner IC, Lundquist CB. Prediction of Motor Outcome in Patients With Severe Upper Limb Impairment After Stroke Using Motor Evoked Potentials. Neurorehabil Neural Repair. 2026 May 15:15459683261442196. doi: 10.1177/15459683261442196. Online ahead of print.

    PubMed 42140614

Questions about this trial

What is this clinical trial studying?

An observational study of Stroke, run by University of Aarhus at 1 site in Denmark.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 4 inclusion and 5 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: under way, not looking for participants, as of the sponsor's last update on 21 May 2025. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Denmark. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Action Research Arm Test (time frame: 3 months after stroke). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT06153017, which also lists 1 linked publication.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 21 May 2025.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in